# Hyun Cheol Chung

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/hyun-cheol-chung/

## Facts

| Field | Value |
| --- | --- |
| Citations | 56,609 |
| Field | Legal and Regulatory Analysis |
| h-index | 88 |
| i10-index | 411 |
| Last Known Institution | Yonsei University |
| OpenAlex ID | https://openalex.org/A5090832721 |
| ORCID iD | https://orcid.org/0000-0002-0920-9471 |
| Works | 1,666 |

## Researcher papers

- [Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort](https://scholariq.org/papers/antitumor-activity-of-pembrolizumab-in-biomarker-unselected-patients-with/)
- [Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial](https://scholariq.org/papers/ramucirumab-versus-placebo-as-second-line-treatment-in-patients-with-advanced/)
- [The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer](https://scholariq.org/papers/the-keynote-811-trial-of-dual-pd-1-and-her2-blockade-in-her2-positive-gastric/)
- [Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment of <i>HER2</i>-Amplified Advanced Gastric Cancer in Asian Populations: TyTAN—A Randomized, Phase III Study](https://scholariq.org/papers/lapatinib-plus-paclitaxel-versus-paclitaxel-alone-in-the-second-line-treatment/)
- [Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study](https://scholariq.org/papers/atezolizumab-with-or-without-bevacizumab-in-unresectable-hepatocellular/)
- [Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4)](https://scholariq.org/papers/safety-and-efficacy-of-nivolumab-in-combination-with-s-1-capecitabine-plus/)

## Researcher topics

- [Legal and Regulatory Analysis](https://scholariq.org/topics/legal-and-regulatory-analysis/)
- [Linguistic, Cultural, and Literary Studies](https://scholariq.org/topics/linguistic-cultural-and-literary-studies/)
- [Military Technology and Strategies](https://scholariq.org/topics/military-technology-and-strategies/)
- [Gastric Cancer Management and Outcomes](https://scholariq.org/topics/gastric-cancer-management-and-outcomes/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)

## Researcher university

- [Yonsei University](https://scholariq.org/institutions/yonsei-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.